Agilon Health (AGL)
(Delayed Data from NYSE)
$5.00 USD
-0.13 (-2.53%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.00 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth A Momentum D VGM
Agilon Health (AGL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.44 | $30.00 | $5.00 | 103.51% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Agilon Health comes to $10.44. The forecasts range from a low of $5.00 to a high of $30.00. The average price target represents an increase of 103.51% from the last closing price of $5.13.
Analyst Price Targets (17)
Broker Rating
Agilon Health currently has an average brokerage recommendation (ABR) of 2.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 2.42 a month ago based on 19 recommendations.
Of the 20 recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 30% and 5% of all recommendations. A month ago, Strong Buy made up 31.58%, while Buy represented 5.26%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 12 | 11 | 11 | 11 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 0 | 0 |
ABR | 2.45 | 2.42 | 2.42 | 2.28 | 2.06 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/29/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
2/29/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
2/28/2024 | Evercore Partners | Elizabeth Anderson | Hold | Hold |
1/8/2024 | SVB Securities | Whit Mayo | Strong Buy | Hold |
12/6/2023 | JMP Securities | Constantine Kyriakos Davides | Not Available | Strong Buy |
11/2/2023 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
11/1/2023 | BTIG | David M Larsen | Not Available | Hold |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.45 |
ABR (Last week) | 2.42 |
# of Recs in ABR | 20 |
Average Target Price | $10.44 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.01 |